Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Webistes |
     
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Financial Results

Contact us

Sanofi India Limited

54/A, Sir Mathuradas Vasanji Road,
Andheri East,
Mumbai 400 093
India

Board Tel.: (91-22) 28278000
Fax: (91-22) 28370939

Content :

Unaudited Financial Results for the Quarter ended June 30, 2012

SANOFI INDIA LIMITED
Registered Office : 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

Part I

(Rs. Million)

ParticularsQuarter ended 30.06.2012
Unaudited
Quarter ended 31.03.2012
Unaudited
Quarter ended 30.06.2011
Unaudited
Half Year ended 30.06.2012
Unaudited
Half Year ended 30.06.2011
Unaudited
Year ended 31.12.2011
(Audited)
1. Income from Operations
(a) Net Sales (net of excise duty)3,7413,2253,0286,9665,79112,297
(b) Other Operating Income185203195388374753
Total income from Operations (net)3,9263,4283,2237,3546,16513,050
2 Expenditure
(a) Cost of Materials Consumed1,4281,3221,3152,7502,5074,916
(b) Purchase of stock in trade5214784909997261,353
(c) Changes in inventories of finished goods, work in progress and stock in trade(98)(215)(299)(313)(366)(76)
(d) Employee benefits expense5484904411,0388461,764
(e) Depreciation and amortisation expense18618354369108311
(f) Other expenses8206586531,4781,2152,579
(g) Total Expenses3,4052,9162,6546,3215,03610,847
3 Profit from Operations before other income and finance costs (1-2)5215125691,0331,1292,203
4 Other Income8286166168364641
5 Profit before finance costs (3+4)6035987351,2011,4932,844
6 Finance costs44-8-4
7 Profit before tax and Exceptional items (5-6)5995947351,1931,4932,840
8 Tax Expense194193238387490928
9 Net Profit for the period before Exceptional items (7-8)4054014978061,0031,912
10 Exceptional item (net of tax)------
11 Net Profit for the period after Exceptional items (9+10)4054014978061,0031,912
12 Paid-up equity share capital
(Face Value of Rs. 10 per Share)
230230230230230230
13 Reserves excluding Revaluation
Reserves as per balance, sheet of previous accounting year
10,781
14 Earnings Per Share (EPS) before Exceptional items (Rs.)
(Basic and diluted EPS for the period, for the year to date and for the previous year)
17.6117.4321.6135.0443.6183.13
15 Earnings Per Share (EPS) after Exceptional items (Rs.)
(Basic and diluted EPS for the period, for the year to date and for the previous year)
17.6117.4321.6135.0443.6183.13

Part II

ParticularsQuarter ended 30.06.2012
Unaudited
Quarter ended 31.03.2012
Unaudited
Quarter ended 30.06.2011
Unaudited
Half Year ended 30.06.2012
Unaudited
Half Year ended 30.06.2011
Unaudited
Year ended 31.12.2011
(Audited)
A. PARTICULARS OF SHAREHOLDING
1 Public Shareholding
- Number of Shares9,121,0359,121,0359,121,0359,121,0359,121,0359,121,035
- Percentage of Shareholding39.60%39.60%39.60%39.60%39.60%39.60%
2 Promoters and Promoter group Shareholding
a) Pledged/Encumbered
- Number of sharesNILNILNILNILNILNIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)NILNILNILNILNILNIL
- Percentage of shares (as a % of total share capital of the company)NILNILNILNILNILNIL
b) Non-encumbered
- Number of shares13,909,58713,909,58713,909,58713,909,58713,909,58713,909,587
- Percentage of shares (as a % of total
shareholding of promoter and promoter group)
100.00%100.00%100.00%100.00%100.00%100.00%
- Percentage of shares (as a % of total share capital of the company)60.40%60.40%60.40%60.40%60.40%60.40%
Particulars3 Months ended June 30,2012
B. INVESTOR COMPLAINTS
Pending at the beginning of the quarterNIL
Received during the quarter32
Disposed of during the quarter32
Remaining unresolved at the end of the quarterNIL

The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:

ParticularsAs at June 30, 2012 UnauditedAs at Dec 31, 2011 Audited
EQUITY AND LIABILITIES :
Shareholders' funds :
(a) Share capital230230
(b) Reserves & Surplus *11,63110,936
Sub-total - Shareholder's Funds11,86111,166
Non-current liabilities
(a) Other long term liabilities1010
(b) Long term provisions362313
(c) Deferred Tax Liabilities (Net)8885
Sub-total - Non-current liabilities460408
Current liabilities
(a) Trade Payables1,4591,435
(b) Other current liabilities656750
(c) Short-term provisions6281,266
Sub-total - Current liabilities2,7433,451
TOTAL EQUITY & LIABILITIES15,06415,025
ASSETS
Non-current assets
(a) Fixed Assets (Including Capital Work in Progress)7,5487,598
(b) Non current investments44
(c) Long term loans and advances599771
(d) Other non-current assets136
Sub-Total - Non Current Assets8,1648,379
Current assets
(a) Inventories2,9962,543
(b) Trade receivables1,2581,040
(c) Cash & Bank Balances2,3452,342
(d) Short term loans & advances239657
(e) Other current assets6264
Sub-total - Current assets6,9006,646
TOTAL ASSETS15,06415,025

* After considering Interim Dividend

Notes:

  • The above Results were approved by the Board of Directors of the Company at its Meeting held on July 25, 2012.
  • In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2012.
  • The Registrar of Companies, Maharashtra approved change of name of the Company from Aventis Pharma Limited to Sanofi India Limited, with effect from May 11, 2012 pursuant to the resolution passed by the Members at the Annual General Meeting held on May 3, 2012.
  • The Board of Directors has declared an Interim Dividend of Rs. 4 per Equity share of Rs. 10 to be paid to those Members whose names appear on the Register of Members of the Company on August 3, 2012 being the Record Date. The said dividend will be paid on August 16, 2012.
  • The profit for the quarter and half year ended June 30, 2012 has been impacted due to the amortization costs relating to the brands and technical know-how acquired in 2011 from Universal Medicare Private Limited and lower interest income as a result of the above investment.
  • The Company has a single business segment namely ‘Pharmaceutical Business’.
  • The figures for the previous periods have been re-grouped, wherever necessary.



SANOFI INDIA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR

Updated July 25, 2012